Basit öğe kaydını göster

dc.contributor.authorYolbaş, Servet
dc.contributor.authorKara, Murat
dc.contributor.authorYılmaz, Musa
dc.contributor.authorAydın, Süleyman
dc.contributor.authorKoca, Süleyman Serdar
dc.date.accessioned2020-11-20T15:02:24Z
dc.date.available2020-11-20T15:02:24Z
dc.date.issued2016
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.urihttps://doi.org/10.1007/s10067-016-3266-1
dc.identifier.urihttps://hdl.handle.net/20.500.12809/2489
dc.descriptionAnnual Meeting of Spondyloarthritis-Research-and-Treatment-Network (SPARTAN) - JUL 25-26, 2015 - Denver, COen_US
dc.descriptionWOS: 000376281000018en_US
dc.descriptionPubMed ID: 27079850en_US
dc.description.abstractAdropin, a secreted protein, is encoded by the energy homeostasis associated (ENHO) gene. It has been implicated in the several physiological and pathological processes such as angiogenesis and apoptosis. Therefore, the aim of present study was to investigate serum adropin levels and ENHO gene expressions in systemic sclerosis (SSc) characterized by vasculopathy, inflammation, and progressive fibrosis of the skin and internal organs. The study includes 27 patients with SSc, 39 patients with Beh double dagger et's disease (BD), and 20 healthy controls (HC). Serum adropin levels and ENHO gene expressions by peripheral blood mononuclear cells were analyzed by ELISA method and by real-time PCR, respectively. The serum adropin levels were higher in the SSc and BD groups than in the HC group (p = 0.023 and p < 0.001, respectively). However, there were no significant differences among the groups in terms of ENHO gene expressions (p (ANOVA) = 0.149). There was no significant difference between the limited and diffuse cutaneous subtypes of SSc in terms of serum adropin level and ENHO gene expression. Moreover, serum adropin level and ENHO gene expression were not associated with the disease activity and severity indexes. ENHO gene expression was correlated with the triglyceride levels in the BD group (r = -0.426, p = 0.027). The augmented serum adropin levels may be expected in the chronic inflammatory disease and seem not to be characteristic of only SSc. However, further studies are needed to explain the precise role of adropin in SSc.en_US
dc.description.sponsorshipSpondyloarthritis Res & Treatment Networken_US
dc.item-language.isoengen_US
dc.publisherSpringer London Ltden_US
dc.item-rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdropinen_US
dc.subjectBehcet's Diseaseen_US
dc.subjectENHOen_US
dc.subjectSystemic Sclerosisen_US
dc.titleSerum adropin level and ENHO gene expression in systemic sclerosisen_US
dc.item-typeconferenceObjecten_US
dc.contributor.departmentMÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorKara, Murat
dc.identifier.doi10.1007/s10067-016-3266-1
dc.identifier.volume35en_US
dc.identifier.issue6en_US
dc.identifier.startpage1535en_US
dc.identifier.endpage1540en_US
dc.relation.journalClinical Rheumatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster